Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Head & Neck 2Gynecologic 2Lymphoid 1

Conditions

Head and Neck Neoplasms 408Squamous Cell Carcinoma of Head and Neck 326Thyroid Neoplasms 104Carcinoma, Non-Small-Cell Lung 85Neoplasms 66Oropharyngeal Neoplasms 59Carcinoma, Squamous Cell 59Melanoma 56Lung Neoplasms 47Neoplasm Metastasis 44Mouth Neoplasms 43Breast Neoplasms 42Laryngeal Neoplasms 39Thyroid Cancer, Papillary 36Salivary Gland Neoplasms 35Colorectal Neoplasms 35Ovarian Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Stomach Neoplasms 30Tongue Neoplasms 28Nasopharyngeal Neoplasms 28Uterine Cervical Neoplasms 27Carcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 24Sarcoma 24Carcinoma, Medullary 24Recurrence 22

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma in Situ × Head & Neck × Clear all
NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

M.D. Anderson Cancer Center

Phase 3 Completed
303 enrolled 11 charts
Head & Neck

Carcinoma in Situ, Mouth Neoplasms

NCT01192204 2015-08-14

Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

Ohio State University

Phase 1/2 Completed
41 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡